Anaplastic thyroid carcinoma with long term survival after combined treatment: case report.
Anaplastic thyroid carcinoma (ATC) is associated with an almost uniformly rapid and lethal clinical course. ATC grows rapidly and invades surrounding tissues at an early stage. Despite surgery, chemotherapy and radiotherapy, few patients with ATC live more than 1 year follow-up diagnosis. The mean survival is reported to be only 7.2 months. Treatment of ATC is still controversial because of its rarity and advanced stage at the time of diagnosis. We report herein an unusual case of ATC, 35 year old woman. She is alive without evidence of recurrence more than 36 months after combined therapy.
Kurukahvecioglu
Osman
O
Gazi University Faculty of Medicine, Department of General Surgery, Ankara, Turkey. okurukahveci@yahoo.com
Ege
Bahadir
B
Poyraz
Aylar
A
Tezel
Ekmel
E
Taneri
Ferit
F
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D043823:Taxoids / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D043823:Taxoids; D000077143:Docetaxel